Description: AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish and explore development of a spray-on treatment for patients with epidermolysis bullosa; and a research collaboration with Houston Methodist Research Institute to explore novel approaches for skin rejuvenation. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. is based in Valencia, California.
Home Page: www.avitamedical.com
28159 Avenue Stanford
Valencia,
CA
91355
United States
Phone:
661 367 9170
Officers
| Name | Title |
|---|---|
| Mr. James M. Corbett | CEO, Pres & Exec. Director |
| Mr. Michael Bria Holder MBA | Chief Financial Officer |
| Ms. Kathy M. McGee | Chief Operating Officer |
| Mr. Andrew Quick | Chief Technology Officer |
| Ms. Donna Shiroma | Gen. Counsel & Sec. |
| Ms. Erin Liberto | Chief Commercial Officer |
| Mr. David Fencil | VP of Global Operations |
| Ms. Debbie Garner | VP of Global Marketing |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.778 |
| Price-to-Sales TTM: | 6.6341 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 116 |